SF2312 amends Iowa Code chapter 510D to add three definitions — “340B drug,” “manufacturer,” and “distributor” — and to prohibit manufacturers and distributors from preventing covered entities from obtaining 340B-priced drugs or from impeding shipments to contract pharmacies. The prohibition applies directly and indirectly but includes a narrow exception when the United States Department of Health and Human Services (HHS) has expressly prohibited the purchase or receipt.
This is a targeted state-level intervention aimed at protecting the 340B supply chain within Iowa. For covered entities and contract pharmacies it reduces a route by which manufacturers or wholesalers could deny access; for manufacturers and distributors it creates a new statutory constraint on distribution practices and contractual controls.
The bill is silent on enforcement mechanisms and remedies, which raises practical and legal implementation questions (including interaction with federal law).
At a Glance
What It Does
The bill inserts statutory definitions for ‘‘340B drug,’’ ‘‘manufacturer,’’ and ‘‘distributor’’ into chapter 510D and adds a prohibition that stops manufacturers and distributors from denying, restricting, or otherwise interfering with a covered entity’s purchase of 340B-priced drugs or delivery to a contract pharmacy. The only carve-out allows such action when HHS has prohibited the purchase or receipt.
Who It Affects
Directly affected parties include drug manufacturers (as defined by reference to the federal Social Security Act), wholesale distributors (including repackers, brokers, jobbers, warehouses and retail pharmacies that do wholesale distribution), covered entities that participate in the 340B program, and contract pharmacies that handle 340B fills. Indirectly affected actors include supply‑chain intermediaries and any Iowa purchasers who rely on contract‑pharmacy arrangements.
Why It Matters
The measure creates a state statutory backstop for 340B participants who contend manufacturers or wholesalers have blocked access or deliveries, narrowing commercial options for manufacturers and distributors. Because it references federal HHS authority as the only exception, the bill sets up a potential tension between state regulation of distribution practices and federal oversight of the 340B program.
More articles like this one.
A weekly email with all the latest developments on this topic.
What This Bill Actually Does
SF2312 takes two concrete steps. First, it adds definitions into Iowa’s drug distribution chapter so the statute explicitly recognizes a ‘‘340B drug’’ (a covered outpatient drug offered at a reduced price under 42 U.S.C. §256b), a ‘‘manufacturer’’ (by cross‑reference to the federal Social Security Act definition), and a broad ‘‘distributor’’ category that reaches repackers, jobbers, brokers, warehouses, independent wholesale traders, and retail community pharmacies that perform wholesale distributions.
Those definitional additions change who the statute speaks to and close a gap where courts or market participants could argue the Code didn’t plainly cover certain intermediaries.
Second, the bill imposes a flat bar on manufacturers and distributors taking actions — whether direct or indirect — that would prevent a covered entity from acquiring a 340B drug or prevent delivery of a 340B drug to a contract pharmacy. The protective language is intentionally broad: it covers restrictions, denials, and other interference, and it captures indirect methods (for example, contractual conditions on distributors or downstream supply‑chain practices).
That breadth is designed to prevent end‑runs where a manufacturer uses a distributor or contractual clause to achieve the same practical result as a direct refusal.The statute, however, contains one clear exception: if HHS has prohibited the purchase or receipt, the state prohibition does not apply. The bill does not identify who enforces the new prohibition, what remedies apply (injunctions, civil penalties, private right of action), or how disputes over whether HHS has prohibited a transaction are to be resolved.
Those implementation details will determine how effective the statutory bar is in practice and whether it triggers litigation over preemption, interstate commerce, or contract conflicts.
The Five Things You Need to Know
The bill amends Iowa Code section 510D.1 by adding three new definitions: “340B drug,” “distributor,” and “manufacturer” (the latter by reference to 42 U.S.C. and the Social Security Act).
Section 510D.2 receives a new subsection that prohibits a manufacturer or distributor from denying, restricting, or otherwise interfering—directly or indirectly—with a covered entity’s acquisition of a 340B drug or delivery to a contract pharmacy.
The prohibition includes an explicit carve‑out: the restriction does not apply when the United States Department of Health and Human Services has prohibited the purchase or receipt of the drug.
The distributor definition expressly includes retail community pharmacies that perform wholesale distributions, bringing some contract pharmacies within the statutory distributor concept.
The bill does not specify enforcement authorities, remedies, civil penalties, or a private right of action, leaving open who enforces the prohibition and how compliance will be adjudicated.
Section-by-Section Breakdown
Every bill we cover gets an analysis of its key sections.
Adds targeted definitions for 340B participants and products
This provision inserts three new definitional subsections. Defining “340B drug” by reference to 42 U.S.C. §256b ties the state statute to the federal program’s scope; defining “manufacturer” by cross‑reference to the Social Security Act imports the existing federal contours of that term; and broadening “distributor” to list repackers, jobbers, brokers, warehouses, independent wholesale drug traders and retail community pharmacies that perform wholesale distribution expands the statute’s reach to a wide set of supply‑chain actors. Practically, these definitions determine who must comply and who can be regulated under the new prohibition.
Prohibits interference with 340B purchases and deliveries, subject to HHS exception
This is the operative clause: it forbids manufacturers or distributors from taking actions—either directly or by indirect means—that would prevent a covered entity from obtaining a 340B drug or stop delivery to a contract pharmacy. The language is deliberately expansive to capture indirect conduct (for example, contractual restrictions on wholesalers). The only statutory exception delegates deference to HHS: if HHS has prohibited the purchase or receipt, the state ban does not apply. The provision does not describe monitoring, investigatory powers, or penalties, so enforcement pathways are left undefined.
Purpose statement and limits of the bill
The bill’s explanation restates the intent to protect 340B access but does not add operative legal requirements beyond the text. That helps interpret legislative intent but does not create new enforcement text. The absence of procedural or remedial language in both sections is a practical gap—courts, agencies, or future amendments will need to supply the mechanics for resolving disputes, determining HHS prohibitions, and imposing remedies.
This bill is one of many.
Codify tracks hundreds of bills on Healthcare across all five countries.
Explore Healthcare in Codify Search →Who Benefits and Who Bears the Cost
Every bill creates winners and losers. Here's who stands to gain and who bears the cost.
Who Benefits
- Federally qualified health centers and safety‑net hospitals that participate in the 340B program — the bill strengthens statutory protection against upstream denials or distribution blocks that limit their ability to obtain discounted drugs.
- Contract pharmacies (retail community pharmacies that fill 340B prescriptions through contract arrangements) — the measure reduces the risk that a manufacturer or wholesaler can lawfully stop deliveries that support contract‑pharmacy fills.
- Patients served by 340B‑participating providers — by protecting supply channels, the bill aims to preserve the financial space providers use to stretch scarce resources for low‑income or uninsured patients.
Who Bears the Cost
- Drug manufacturers — they face a new state statutory restriction on distribution controls and may need to revise contracts and distribution policies to avoid claims of unlawful interference.
- Wholesale distributors, brokers, and repackers — the expanded distributor definition pulls more intermediaries into the statute’s scope, increasing compliance monitoring and potentially constraining contractual terms with manufacturers.
- Iowa regulators and courts — because the bill omits enforcement language, state agencies or courts may absorb disputes, interpret the HHS exception, and adjudicate conflicts without a clear administrative mechanism, creating potential administrative burdens and litigation costs.
Key Issues
The Core Tension
The bill pits two legitimate aims against each other: ensuring that safety‑net providers and their contract pharmacies can access discounted 340B drugs, versus limiting manufacturers’ and distributors’ control over how and to whom they sell and ship products—control they argue is necessary to comply with federal program rules and commercial contracts. Resolving access without creating regulatory conflicts or unintended supply disruptions is the central dilemma.
The bill’s protective scope is clear but leaves critical implementation questions unanswered. Chief among these is enforcement: the statute does not designate an enforcing agency, create civil penalties, or establish a private right of action.
Absent those mechanics, covered entities may have only the option of seeking judicial relief under general statutory or common‑law causes, which could be slow and uncertain. Another issue is how to determine when HHS has ‘‘prohibited’’ a purchase or receipt; HHS guidance or federal rulemaking could be ambiguous, and the bill gives no process for resolving competing interpretations.
There is also a legal friction with federal oversight of the 340B program. By tying the exception to HHS prohibitions, the bill acknowledges federal authority but does not resolve preemption or interstate commerce questions that could arise if manufacturers alter national distribution in response to state constraints.
Operationally, the broad terms “restrict” and “interfere” capture many business practices, which may prompt defensive contracting or withdrawal of products from certain channels, potentially shrinking availability despite the law’s protective intent.
Try it yourself.
Ask a question in plain English, or pick a topic below. Results in seconds.